Insulin Pump Data

T1D pump penetration has almost doubled in the past 15 years as product feature sets have been added (e.g., CGM integration) and outcomes from automated insulin delivery have shown significant reductions in hypoglycemia and increases in time-in-range.

Medtronic has historically led the domestic pump market in share (over 70%) but recent competitive launches from Tandem and Insulet have eroded this to under 50%. Animas, Smiths and Roche all exited the domestic pump market but newer players like CeQur are poised to take their place.

A number of new players are slated to commercialize T2D-oriented insulin pumps in the next couple of years — some with basal-bolus capability and some with bolus-only mechanics for mealtime insulin delivery. Mannkind and CeQur currently offer T2D-focused patch pumps.

Online research and insurance coverage levels are the two most influencial sources for people when they are shopping for a pump, with DTC ads scoring last. The most important pump features include CGM integration and overall ease-of-use.

Insulin pumps were brought to the mainstream market by MiniMed and Disetronic and have experienced four main development epochs since the early 1990s. We are currently in the Automated Insulin Delivery Era with three major approved systems in Control IQ, Omnipod 5 and Medtronic’s 770G.

The push for AID systems began in Europe with the MiniMed VEO which suspended pump delivery upon detection of low glucose values. Medtronic’s 780G is now available in select European countries, competing with Tandem’s Control-IQ and Roche’s Diabeloop-enabled system.

The domestic pump market consists of five commercilaized products with Omnipod 5 being the newest offering. Both Tandem and Insulet are integrated with the Dexcom CGM, while Medtronic offers its own pump, consumables, and CGM.

In addition to pumps, there are alternative insulin delivery systems that are highly differentiated from traditional pens and syringes. These devices provide many of the benefits of pump therapy without tubing or technical complexity.

Outside of the United States, there other pump players, notably Roche (partnered with Diabeloop) and Ypsomed (partnered with Eli Lilly). Tandem and Insulet are expanding into international markets where Medtronic and Roche still hold significant share.